{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216745","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2026-05-11T20:05:24+00:00","discovered_at":"2026-05-11T20:07:00.351027+00:00","generated_at":"2026-05-11T22:51:16.951019+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"AnaptysBio appoints Christopher Murphy CFO ($42,917/mo) and Owen Hughes to board","bullets":["Christopher Murphy appointed CFO effective May 11, 2026; previously CFO at Third Harmonic Bio and Horizon Therapeutics.","Murphy's consulting agreement: $42,916.66 monthly fee, target bonus up to 40% of annual fees, and $1.75M RSU grant vesting over 4 years.","Owen Hughes appointed Class I director effective May 11, 2026; receives initial grant of 11,250 RSUs vesting over 3 years.","Murphy serves as independent contractor; severance provides 9-12 months fee continuation based on termination cause."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216745","json":"https://secwatch.observer/filing/0001193125-26-216745.json","markdown":"https://secwatch.observer/filing/0001193125-26-216745.md","text":"https://secwatch.observer/filing/0001193125-26-216745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000119312526216745/0001193125-26-216745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000119312526216745/anab-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:51:16.951019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ea70cb032","claim":"Christopher M. Murphy was appointed as Chief Financial Officer at ANAPTYSBIO, INC.","evidence_excerpt":"On May 11, 2026, AnaptysBio, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000119312526216745/0001193125-26-216745-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}